Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 7, 2011, Pages 542-547

  Abou Zeid, Abla A ^a   Azzam, Amal Z ^a   Kamel, Nahla A ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cyclin dependent kinase inhibitor 2; DNA methylation; DNA testing; gene silencing; ovarian cancer; real time PCR; tumor suppressor genes

Indexed keywords

CA 125 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BIOPSY; CA-125 ANTIGEN; CARCINOMA; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EGYPT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 80054082825     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.590224     Document Type: Article

References (27)

1. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;29:2705-12. (Pubitemid 38725419)
2. Yuasa Y. Epigenetics in molecular epidemiology of cancer a new scope. Adv Genet 2010;71:211-35.
3. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14: R65-R76. (Pubitemid 40542622)
4. Jo UH, Whang YM, Sung JS, Kim YH. Methylation of AKAP12{alpha} promoter in lung cancer. Anticancer Res 2010;30:4595-600.
5. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129-39.
6. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of Sparc in ovarian cancer. Neoplasia 2009;11: 126-35.
7. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 2009;45:1129-36.
8. Furtado YL, Almeida G, Lattario F, Silva KS, Maldonado P, Silveira FA, do Val IC, Fonseca R, Carvalho Mda G. The presence of methylation of the p16INK4A gene and human papillomavirus in high-grade cervical squamous intraepithelial lesions. Diagn Mol Pathol 2010;19:15-9.
9. Goto T, Mizukami H, Shirahata A, Yokomizo K, Kitamura YH, Sakuraba K, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K. Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer. Anticancer Res 2010;30:2701-3.
10. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynecol Obstet 2003;83(Suppl. 1):135-66. (Pubitemid 39658498)
11. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
12. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-31.
13. Surowiak P, Materna V, Maciejczyk A, Pudelko M, Suchocki S, Kedzia W, Nowak-Markwitz E, Dumanska M, Spaczynski M, Zabel M, Dietel M, Lage H. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol Histopathol 2008;23:531-8. (Pubitemid 351552339)
14. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006;107:299-308. (Pubitemid 44036559)
15. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO. Promoter hypermethylation profi le of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:5365-9. (Pubitemid 41060809)
16. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF. Methylation profi les of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002;8:3324-31. (Pubitemid 35340705)
17. De Caceres II, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P. Tumor cell-specifi c BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fl uid from ovarian cancer patients. Cancer Res 2004;64:6476-81. (Pubitemid 39297903)
18. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R. CpG Island Methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961-7. (Pubitemid 41377387)
19. McCluskey L, Chen C, Delgadillo E, Felix JC, Muderspach L, Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999;72:87-92. (Pubitemid 29045453)
20. Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P. CpG methylation analysis - current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn 2009;11:266-78.
21. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of sodium bisulfi te conversion and realtime PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-17. (Pubitemid 43811244)
22. Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, Choi C, Fackler MJ, Sukumar S. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol Oncol 2010;118:176-81.
23. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001;158:1121-7. (Pubitemid 32221804)
24. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
25. Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:210-8.
26. Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T, Ushijima T. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett 2006;241: 213-20. (Pubitemid 44163031)
27. Milde-Langosch K, Ocon E, Becker G, Loning T. p16/ MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998;79:61-5. (Pubitemid 28157728)